A Look At Luye Pharma Group (SEHK:2186) Valuation As LY03020 Enters Phase II For Schizophrenia

Luye Pharma Group (SEHK:2186) has drawn fresh attention after reporting the first patient enrollment in a Phase II trial in China for LY03020, a dual TAAR1 and 5-HT2CR agonist targeting schizophrenia.

See our latest analysis for Luye Pharma Group.

The LY03020 trial update comes as Luye Pharma Group’s share price sits at HK$2.89, with a 30-day share price return of 18.93% contrasting with a 90-day share price decline of 3.99%. The 1-year total shareholder return of 55.38% stands against a 3-year total shareholder return decline of 25.90%, which may indicate improving momentum following a weaker multi year period.

If you are looking beyond a single drug developer, this could be a useful moment to broaden your watchlist and check out 124 healthcare AI stocks

With LY03020 advancing and Luye Pharma Group trading at HK$2.89 alongside an indicated intrinsic discount and a value score of 4, the key question is whether this reflects an undervalued entry or whether the market is already pricing in future growth.

Preferred P/E of 16.2x: Is it justified?

The current P/E of 16.2x at a share price of HK$2.89 sits below both Luye Pharma Group’s estimated fair P/E of 21.7x and the peer average of 23.5x. This signals a lower valuation relative to those benchmarks even though it is slightly higher than the Hong Kong Pharmaceuticals industry average of 15.3x.

The P/E multiple links what you pay today to the earnings the company is currently generating, which is especially relevant for a business already producing profits. For Luye Pharma Group, this links HK$2.89 per share to earnings that have been growing, with the P/E helping you gauge how much the market is paying for that profit base versus what a regression based fair ratio suggests might be reasonable.

Here, the market is assigning a P/E that is cheaper than both the estimated fair P/E of 21.7x and the peer average of 23.5x, yet slightly richer than the industry’s 15.3x. That mix points to a company priced below what the SWS fair ratio model indicates the multiple could move toward over time, while still acknowledging its stronger earnings profile than the broader industry.

Explore the SWS fair ratio for Luye Pharma Group

Result: Preferred Price-to-Earnings of 16.2x (UNDERVALUED)

However, you also need to weigh the 3 year and 5 year total shareholder return declines, as well as execution risk around LY03020 and wider product performance.

Find out about the key risks to this Luye Pharma Group narrative.

Another way to look at value

The SWS DCF model paints a different picture, with Luye Pharma Group at HK$2.89 compared with an estimated future cash flow value of HK$8.23. That gap suggests the cash flow view also points to an undervalued stock. The key question is what factors could close or widen that spread over time.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Luye Pharma Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 222 high quality undervalued stocks. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

Next Steps

Seeing both potential upside and clear risks in the story so far, this is a good time to check the numbers yourself and pressure-test the thesis. To round out your view, take a closer look at the 3 key rewards

Looking for more investment ideas?

If you stop here, you might miss other opportunities that fit your style, so use the tools available and let the data help you spot what stands out.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com